SCHEMBL131017

SCHEMBL131017

C=CCCCCCCCCCCCCCN

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.52
DNM1 Q05193 4/20 0.50
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA3 P07451 2/20 0.50
CA4 P22748 2/20 0.50
CA6 P23280 2/20 0.50
CA5A P35218 2/20 0.50
CA7 P43166 2/20 0.50
CA9 Q16790 2/20 0.50
CA14 Q9ULX7 2/20 0.50
CA5B Q9Y2D0 2/20 0.50
LMNA P02545 1/20 0.50
BLM P54132 1/20 0.50
ABCC4 O15439 1/20 0.44
MAPT P10636 1/20 0.44
NFKB1 P19838 1/20 0.44
ALDH1A1 P00352 3/20 0.43
TRPA1 O75762 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL131171 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL2140212 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL133481 1.00
SCHEMBL19774576 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL132137 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL129565 1.00
SCHEMBL130220 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL8954646 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL3168896 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2
SCHEMBL130546 1.00 TSHR (0.52) TSHRDNM1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119264963-A Mannich ashless dispersant, lubricating oil composition and application thereof 中国石油天然气股份有限公司 2025-01-07 CN claimed
US-20260035391-A1 SILANE COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2026-02-05 US disclosed
EP-4678645-A1 SILANE COMPOUND Daikin Industries, Ltd. (JP) 2026-01-14 EP disclosed
US-20250361250-A1 FLUORINE-CONTAINING SILANE COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2025-11-27 US disclosed
WO-2025028568-A1 SURFACE TREATMENT AGENT ダイキン工業株式会社 2025-02-06 WO disclosed
CN-119264963-A Mannich ashless dispersant, lubricating oil composition and application thereof 中国石油天然气股份有限公司 2025-01-07 CN disclosed
WO-2024214748-A1 SILANE COMPOUND ダイキン工業株式会社 2024-10-17 WO disclosed
WO-2024172034-A1 FLUORINE-CONTAINING SILANE COMPOUND ダイキン工業株式会社 2024-08-22 WO disclosed
EP-3269395-A1 AMINOALCOHOL LIPIDOIDS AND USES THEREOF Massachusetts Institute Of Technology (US) 2018-01-17 EP disclosed
EP-1512397-B1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INST MED MOLECULAR DESIGN INC (JP) 2014-10-08 EP disclosed
EP-1555018-A1 REMEDIES FOR NEURODEGENERATIVE DISEASES Institute of Medicinal Molecular Design, Inc. (JP) 2005-07-20 EP disclosed
EP-1535610-A1 THERAPEUTIC AGENT FOR CANCER Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 EP disclosed
EP-1535609-A1 NF-KB ACTIVATION INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 EP disclosed
EP-1514544-A1 ANTIALLERGIC Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-16 EP disclosed
EP-1512397-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-09 EP disclosed
EP-1512396-A1 INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-09 EP disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
EP-1510210-A1 IMMUNITY-RELATED PROTEIN KINASE INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035391-A1 SILANE COMPOUND OXER1, CBR1, MSR1 TSHR 1167/4885DNM1 1157/4885CA12 544/4885
US-20250361250-A1 FLUORINE-CONTAINING SILANE COMPOUND FLI1, AFF1, RFT1 TSHR 2035/4885DNM1 807/4885CA12 831/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB TSHR 4035/4885DNM1 4569/4885CA12 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.